# TLR4 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - TLR4 is a pattern recognition receptor critical for detecting Gram-negative bacterial lipopolysaccharide (LPS) and damage-associated molecular patterns (DAMPs), initiating innate immune responses via MyD88-dependent (NF-κB activation) and TRIF-dependent (IRF3 activation, Type I IFN production) pathways. - The *TLR4* gene's expression is tightly regulated by promoter elements, epigenetic modifications (DNA methylation, histone acetylation), and alternative splicing, influencing its role in diverse pathologies from sepsis to cancer. - Structural analysis reveals TLR4 functions as a heterodimer with MD-2, forming a complex that binds LPS, leading to downstream signaling initiation through its intracellular TIR domain and recruitment of adaptors like Mal and TRAM. - Common human polymorphisms, such as Asp299Gly (D299G) and Thr399Ile (T399I), located in the extracellular LRR domain, are associated with altered LPS responsiveness and variable clinical outcomes in infectious, autoimmune, and oncological diseases. - TLR4 is a significant therapeutic target, with small-molecule inhibitors (e.g., TAK-242, Eritoran), monoclonal antibodies, and nucleic acid-based therapies (siRNA, microRNAs) being developed to modulate its activity in inflammatory conditions and cancer. - TLR4 plays a crucial role in host-pathogen interactions, recognizing bacterial (LPS), viral, and fungal components, and is implicated in veterinary diseases like mastitis, with specific gene variants correlating to disease resistance. --- ## Executive Summary & Key Metadata Toll-like receptor 4 (TLR4) is the prototypical pattern recognition receptor (PRR) of the innate immune system, best characterized for its indispensable role in the detection of Gram-negative bacterial lipopolysaccharide (LPS). The gene encoding TLR4 was functionally identified through positional cloning of the classical *Lps* locus in mice, where two naturally occurring mutant alleles—*Lpsᵈ* (C3H/HeJ) and *Lpsⁿ* (C57BL/10ScCr)—were found to confer profound endotoxin resistance [1], [2]. This discovery established TLR4 as the long-sought signaling receptor for endotoxin and inaugurated the modern era of innate immunity research. Beyond its canonical role in host defense, TLR4 is now recognized as a critical nexus integrating inflammatory, metabolic, and oncogenic signaling. It responds not only to pathogen-associated molecular patterns (PAMPs) such as LPS, but also to a diverse array of damage-associated molecular patterns (DAMPs) including fibronectin EDA domains, heat shock proteins, HMGB1, and saturated fatty acids [3], [4], [5]. This broad ligand specificity positions TLR4 at the interface of infection, sterile inflammation, autoimmunity, neurodegeneration, and cancer. Consequently, TLR4 has emerged as a high-value therapeutic target across a spectrum of diseases, from sepsis and acute lung injury to Alzheimer's disease, diabetic complications, and multiple malignancies. The following table summarizes the key genomic and proteomic identifiers for TLR4. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | TLR4 | | **UniProt Accession** | O00206 | | **Representative PDB ID** | 3FXI (human TLR4-MD-2-LPS complex) | | **Chromosomal Locus** | 9q33.1 (human); Chromosome 4 (mouse, *Lps* locus) | | **Primary Molecular Function** | Pattern recognition receptor; LPS sensor; activation of NF-κB and IRF3 signaling | | **Disease & Pathology Associations** | Sepsis, endotoxemia, asthma, atherosclerosis, type 2 diabetes, Alzheimer's disease, cancer, inflammatory bowel disease, Behçet's disease, rheumatoid arthritis, mastitis (bovine), tuberculosis | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *TLR4* gene is located on the long arm of chromosome 9 at cytogenetic band 9q33.1. The gene spans approximately 19 kilobases (kb) of genomic DNA and is oriented on the minus strand (reverse orientation) relative to the chromosome. The genomic architecture comprises three exons interspersed with two introns. Exon 1 is entirely non-coding (5' untranslated region, 5' UTR), exon 2 contains a small portion of the 5' UTR and the initiating methionine codon, and exon 3 is the largest exon, encoding the vast majority of the open reading frame (ORF), including the entire extracellular domain, the transmembrane helix, and the intracellular Toll/Interleukin-1 receptor (TIR) domain. The full-length coding sequence (CDS) is 2,526 nucleotides, encoding a precursor protein of 839 amino acids (UniProt O00206). The mouse *Tlr4* gene resides on chromosome 4, within the historically defined *Lps* locus. The two classical mutant alleles—*Lpsᵈ* (a missense mutation substituting proline for histidine at position 712, H712P, within the TIR domain) and *Lpsⁿ* (a complete deletion of the gene)—were instrumental in confirming the identity of TLR4 as the LPS receptor [1], [2]. These natural mutants provided the first genetic proof of TLR4's non-redundant role in endotoxin signaling. ### 1.2 Promoter Architecture and Transcription Factor Binding The proximal promoter of *TLR4* lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for constitutive and inducible transcription factors. Functional dissection of the mouse *Tlr4* promoter identified critical roles for Ets family transcription factors, AP-1 (activator protein-1), and GATA-like motifs in driving basal and LPS-inducible expression in macrophages [6]. The promoter also harbors binding sites for C/EBP (CCAAT/enhancer-binding protein) family members, particularly C/EBPδ, which participates in a positive feedback loop: LPS induces C/EBPδ, which in turn binds the *Tlr4* promoter to amplify TLR4 expression, thereby sustaining the inflammatory response [7]. This feed-forward amplification is negatively regulated by the E3 ubiquitin ligase FBXW7α, which targets C/EBPδ for proteasomal degradation, thus attenuating *Tlr4* transcription and limiting excessive inflammation [7]. In the bovine *TLR4* gene, single-nucleotide polymorphisms (SNPs) in the 5' upstream region have been shown to alter transcription factor binding sites and correlate with differential expression profiles, underscoring the regulatory importance of non-coding variants in this gene [8]. Similarly, the porcine *TLR4* promoter has been characterized, revealing conserved regulatory elements across mammals [1]. ### 1.3 Enhancer Elements and Epigenetic Regulation Epigenetic mechanisms play a central role in the cell-type-specific and stimulus-dependent regulation of *TLR4* expression. In intestinal epithelial cells, the gut microbiota induces DNA methylation at the *TLR4* promoter via a DNA methyltransferase recruited by an adaptor molecule, resulting in transcriptional silencing and suppression of inflammatory reactions [2]. This microbiota-dependent epigenetic silencing is essential for maintaining intestinal homeostasis and preventing chronic colitis [3]. Conversely, in chronic periodontitis, altered promoter methylation status of *TLR4* has been observed, linking epigenetic dysregulation to inflammatory disease [4]. Histone acetylation also governs *TLR4* expression. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) attenuates post-seizure microglial TLR4/MYD88 signaling by increasing histone acetylation at the *TLR4* promoter, thereby modulating gene expression in the context of epilepsy [5]. These findings illustrate that *TLR4* expression is exquisitely controlled at multiple epigenetic layers, integrating environmental cues (microbiota, inflammation, pharmacological agents) with transcriptional output. ### 1.4 Alternative Splicing and Isoforms Alternative splicing of the *TLR4* transcript generates multiple isoforms with potentially distinct functional properties. In ducks, alternative splicing of the *TLR4* gene produces at least two isoforms, one of which lacks a portion of the extracellular leucine-rich repeat (LRR) domain, potentially altering ligand recognition [6]. In grass carp, a cluster of *tlr4* genes has been identified, with differential splicing contributing to the response to grass carp reovirus [7]. In humans, several splice variants have been catalogued in Ensembl, including isoforms that lack the transmembrane domain (potentially encoding soluble TLR4) or that introduce premature stop codons. The functional significance of these human isoforms remains an active area of investigation, but soluble TLR4 variants could act as decoy receptors, modulating LPS responsiveness. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The TLR4 protein is a type I transmembrane glycoprotein of 839 amino acids, organized into three principal domains: an N-terminal ectodomain (ECD), a single-pass transmembrane helix, and a C-terminal cytoplasmic TIR domain. The ECD is responsible for ligand recognition and is composed of 22 tandem copies of the leucine-rich repeat (LRR) motif, a structural module that forms a curved, solenoid-shaped horseshoe architecture. Each LRR is 20–30 residues in length and contains the conserved consensus sequence LxxLxLxxNxL, where L is leucine, x is any amino acid, and N is asparagine. The concave inner surface of the LRR solenoid is lined with β-strands and is the primary site of ligand and co-receptor interaction. The transmembrane domain is a single α-helix of approximately 21 hydrophobic residues that anchors the receptor in the plasma membrane. The C-terminal TIR domain (approximately 150 residues) is the signaling module, structurally conserved across the Toll/IL-1 receptor superfamily. The TIR domain adopts a flavodoxin-like fold consisting of a central five-stranded parallel β-sheet surrounded by five α-helices. The BB-loop, a surface-exposed loop connecting the second β-strand and the second α-helix, is critical for homotypic protein-protein interactions with downstream adaptor molecules. The classical C3H/HeJ mutation (H712P) resides within this BB-loop, explaining the complete loss of signaling in these mice [1], [2]. ### 2.2 Quaternary Structure: The TLR4-MD-2-LPS Complex TLR4 does not function as a monomer. It forms a heterodimer with the secreted glycoprotein MD-2 (myeloid differentiation factor-2, also known as LY96), which is essential for LPS recognition. The crystal structure of the human TLR4-MD-2-LPS complex (PDB: 3FXI) revealed the molecular basis of LPS sensing. MD-2 binds to the concave surface of the TLR4 ECD, forming a hydrophobic pocket that accommodates the lipid A moiety of LPS. Upon LPS binding, a second TLR4 molecule is recruited, forming a symmetric TLR4-MD-2-LPS-TLR4 complex (the "M-shaped" dimer). This dimerization brings the two cytoplasmic TIR domains into close proximity, nucleating the assembly of the intracellular signaling complex. The structural basis of the two common human polymorphisms—Asp299Gly (D299G, rs4986790) and Thr399Ile (T399I, rs4986791)—has been investigated. These SNPs are located in the extracellular LRR region and have been reported to attenuate LPS responsiveness, although the magnitude of the effect is debated. Structural modeling suggests that D299G disrupts a hydrogen-bonding network in LRR10, potentially destabilizing the ECD and reducing MD-2 binding affinity. ### 2.3 Post-Translational Modifications TLR4 is heavily glycosylated, with multiple N-linked glycosylation sites in the ECD. Glycosylation is required for proper folding, trafficking to the cell surface, and ligand recognition. The ECD also contains several cysteine residues that form disulfide bonds, stabilizing the LRR solenoid. Palmitoylation of cytoplasmic cysteine residues has been reported to regulate TLR4 partitioning into lipid rafts, which is a prerequisite for efficient signaling. Additionally, acetylation of lysine residues within the TIR domain of TLR4 and its adaptors (Mal and MyD88) has recently been shown to modulate signaling complex formation and the intensity of the inflammatory response in sepsis [8]. ### 2.4 Interactive 3D Visualization For a comprehensive, interactive exploration of the TLR4 three-dimensional structure, including the full-length receptor, the MD-2 co-receptor, and the LPS ligand, the following resource is recommended: [Interactive 3D Protein Visualizer: Load TLR4 (PDB: 3FXI)](/tools/protein-structure-viewer?source=alphafold&accession=O00206) This visualizer allows users to rotate the complex, highlight individual domains, and examine the atomic contacts between TLR4, MD-2, and lipid A. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical LPS Signaling: The MyD88-Dependent Pathway The binding of LPS to the TLR4-MD-2 complex initiates a cascade of intracellular signaling events. Upon ligand-induced dimerization, the TIR domains of two TLR4 molecules recruit the TIR domain-containing adaptor protein MyD88 (myeloid differentiation primary response 88) through homotypic TIR-TIR interactions. This recruitment is facilitated by the bridging adaptor Mal (MyD88 adaptor-like protein, also known as TIRAP), which is localized to the plasma membrane via a phosphatidylinositol 4,5-bisphosphate (PIP2)-binding domain. The TLR4-Mal-MyD88 complex then nucleates the assembly of the Myddosome, a helical signaling platform composed of MyD88, IRAK4 (IL-1 receptor-associated kinase 4), and IRAK1/2. IRAK4 phosphorylates IRAK1, which then dissociates from the complex and interacts with TRAF6 (TNF receptor-associated factor 6). TRAF6, in conjunction with the E2 ubiquitin-conjugating enzyme UBC13, catalyzes the synthesis of K63-linked polyubiquitin chains on itself and on target proteins. This ubiquitination event activates the TAK1 (TGF-β-activated kinase 1) complex, which in turn phosphorylates the IKK complex (IκB kinase α/β/γ). Activated IKKβ phosphorylates IκBα, targeting it for K48-linked ubiquitination and proteasomal degradation. The liberation of NF-κB (p50/p65 heterodimer) allows its nuclear translocation and the transcriptional activation of pro-inflammatory cytokine genes (TNF-α, IL-1β, IL-6, IL-12), chemokines, and adhesion molecules. ### 3.2 The TRIF-Dependent Pathway Following LPS stimulation, the TLR4-MD-2 complex is internalized into endosomes. From this intracellular compartment, TLR4 recruits the adaptor TRIF (TIR domain-containing adaptor-inducing interferon-β, also known as TICAM1) via the bridging adaptor TRAM (TRIF-related adaptor molecule, also known as TICAM2). TRIF activates two parallel signaling branches. First, it interacts with TRAF3, which recruits TBK1 (TANK-binding kinase 1) and IKKε. These kinases phosphorylate IRF3 (interferon regulatory factor 3), leading to its dimerization and nuclear translocation, where it drives the expression of type I interferons (IFN-α/β) and interferon-stimulated genes (ISGs) [1]. Second, TRIF interacts with RIPK1 (receptor-interacting protein kinase 1), which activates the IKK complex via a TRAF6-independent mechanism, contributing to late-phase NF-κB activation. The TRIF pathway is essential for the full repertoire of TLR4-induced immune responses, including the maturation of dendritic cells and the priming of adaptive immunity. ### 3.3 Non-Canonical Signaling and Metabolic Reprogramming TLR4 signaling extends beyond the classical NF-κB and IRF3 axes. In macrophages, TLR4 activation by LPS induces a profound metabolic reprogramming, shifting cellular metabolism toward aerobic glycolysis (the Warburg effect) to support the rapid synthesis of inflammatory mediators. This metabolic switch is mediated by the transcription factor HIF-1α and is essential for the pro-inflammatory phenotype. Intriguingly, TLR4 has been shown to mediate lipid-induced inflammation not by directly binding saturated fatty acids, but by reprogramming macrophage metabolism, leading to the production of pro-inflammatory lipid species [5]. This finding reframes the role of TLR4 in metabolic diseases such as obesity and type 2 diabetes, where chronic low-grade inflammation is a hallmark [4]. ### 3.4 Regulation and Negative Feedback TLR4 signaling is tightly regulated by multiple negative feedback mechanisms to prevent excessive inflammation and tissue damage. These include: - **Suppressors of cytokine signaling (SOCS):** LPS induces SOCS1 and SOCS3, which inhibit JAK-STAT signaling downstream of cytokine receptors. - **A20 (TNFAIP3):** A deubiquitinase that removes K63-linked ubiquitin chains from TRAF6, terminating NF-κB signaling. - **IRAK-M:** A kinase-dead IRAK family member that inhibits Myddosome assembly. - **MicroRNAs:** miR-146a and miR-223 directly target TLR4 and downstream signaling components, dampening the inflammatory response [2], [3]. - **Epigenetic silencing:** As described above, DNA methylation and histone modifications can durably suppress *TLR4* transcription [2], [3]. - **Metabolic resolution:** The transcription factor SREBP1 contributes to the resolution phase of TLR4 signaling by reprogramming fatty acid metabolism, promoting the synthesis of anti-inflammatory lipid species [4]. ### 3.5 Protein-Protein Interaction Networks The TLR4 signaling complex is a highly dynamic macromolecular assembly. Key protein-protein interactions include: - **TLR4-MD-2:** Essential for LPS binding. - **TLR4-CD14:** CD14, a GPI-anchored protein, facilitates the transfer of LPS to the TLR4-MD-2 complex, enhancing sensitivity. - **TLR4-Mal-MyD88:** Initiates the MyD88-dependent pathway. - **TLR4-TRAM-TRIF:** Initiates the TRIF-dependent pathway. - **TLR4-TIRAP:** The acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates the strength and duration of signaling in sepsis [8]. STRING and BioGRID databases list hundreds of physical and functional interactors for TLR4, reflecting its central position in the innate immune signaling network. ### 3.6 Signaling Pathway Diagram The following Mermaid diagram summarizes the major TLR4 signaling cascades: ```mermaid flowchart TD LPS["Lipopolysaccharide (LPS)"] --> CD14["CD14"] CD14 --> MD2["MD-2"] MD2 --> TLR4["TLR4"] TLR4 -->|"Dimerization"| COMPLEX["TLR4-MD-2-LPS-TLR4"] COMPLEX -->|"Plasma Membrane"| MYD88["MyD88-Dependent Pathway"] COMPLEX -->|"Endosome"| TRIF["TRIF-Dependent Pathway"] MYD88 --> MAL["Mal/TIRAP"] MAL --> IRAK["IRAK1/4"] IRAK --> TRAF6["TRAF6"] TRAF6 --> TAK1["TAK1"] TAK1 --> IKK["IKK Complex"] IKK --> IKBA["IκBα Degradation"] IKBA --> NFKB["NF-κB"] NFKB --> PROINFLAMMATORY["Pro-inflammatory Cytokines: TNF-α, IL-1β, IL-6"] TRIF --> TRAM["TRAM/TICAM2"] TRAM --> TRAF3["TRAF3"] TRAF3 --> TBK1["TBK1/IKKε"] TBK1 --> IRF3["IRF3"] IRF3 --> TYPE1IFN["Type I Interferons: IFN-α/β"] PROINFLAMMATORY --> INFLAMMATION["Inflammation"] TYPE1IFN --> INFLAMMATION ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 The Classical Mouse Mutations The two naturally occurring mouse mutations at the *Lps* locus provided the foundational evidence for TLR4's function. The C3H/HeJ strain carries a missense mutation (H712P) in the TIR domain, which abolishes signal transduction while preserving ligand binding. The C57BL/10ScCr strain carries a complete deletion of the *Tlr4* gene, resulting in a null phenotype [1], [2]. Both strains are hyporesponsive to LPS and highly susceptible to Gram-negative infections, demonstrating the essential role of TLR4 in host defense. ### 4.2 Human Non-Synonymous Polymorphisms Two common non-synonymous SNPs in the human *TLR4* gene have been extensively studied: - **Asp299Gly (D299G, rs4986790):** Located in LRR10 of the ECD. This variant has been associated with reduced LPS responsiveness and an increased risk of Gram-negative sepsis, but also with protection against certain autoimmune and inflammatory diseases. - **Thr399Ile (T399I, rs4986791):** Located in LRR15. This variant frequently co-segregates with D299G (linkage disequilibrium) and is also associated with blunted LPS signaling. The clinical associations of these variants are diverse and sometimes contradictory, reflecting the complex role of TLR4 in different disease contexts: - **Infectious diseases:** D299G has been associated with increased susceptibility to septic shock, pulmonary tuberculosis [5], [6], [7], [8], and *Helicobacter pylori* infection [1]. However, other studies have found no association, and the effect size is likely modest. - **Inflammatory and autoimmune diseases:** D299G/T399I have been associated with a reduced risk of diabetic neuropathy [2], protection against type 2 diabetes [3], and a reduced risk of hepatitis C virus-induced hepatocellular carcinoma [4]. Conversely, associations with Behçet's disease [5], [6], rheumatoid arthritis [7], [8], and inflammatory bowel disease [1] have been reported, though results are inconsistent. - **Cancer:** A meta-analysis concluded that TLR4 polymorphisms, particularly D299G, are associated with reduced cancer susceptibility, especially for gastrointestinal cancers [2]. However, other studies have found no association [3]. - **Allergic and respiratory diseases:** TLR4 variants modify the effects of endotoxin exposure on asthma risk [4] and are associated with tonsillar disease [5]. ### 4.3 Non-Coding Variants and Disease Association Beyond the two well-studied missense SNPs, numerous non-coding variants in the *TLR4* gene have been associated with disease. For example: - **rs2149356:** Associated with primary gouty arthritis, likely by modulating TLR4 expression and the IL-1β response to monosodium urate crystals [6]. - **rs1927914 and rs10759932:** Associated with primary open-angle glaucoma in Chinese and Mexican populations [7], [8]. - **rs4986790 (D299G):** Also associated with major depressive disorder and antidepressant efficacy [1]. - **5' upstream region SNPs (bovine):** Associated with differential expression and mastitis resistance [8], [2], [3]. ### 4.4 TLR4 in Veterinary Medicine TLR4 polymorphisms are of significant economic importance in livestock: - **Mastitis in cattle and buffaloes:** Multiple studies have associated TLR4 SNPs with somatic cell score (a proxy for mastitis) and mastitis resistance [4], [5], [6], [7], [2], [3]. The CRBR2 fragment of the bovine TLR4 gene has been molecularly characterized in this context [4]. - **Salmonella resistance in chickens:** TLR4 genotypes are associated with resistance to *Salmonella enteritidis* infection in kampung chickens [8]. - **Mycobacterium avium subsp. paratuberculosis in cattle:** TLR4 mutations are associated with natural resistance to Johne's disease [1]. ### 4.5 TLR4 in Neurological and Psychiatric Disorders TLR4 is expressed in microglia and neurons, where it mediates neuroinflammation: - **Alzheimer's disease (AD):** TLR4 expression is upregulated in AD brains, and TLR4 signaling contributes to amyloid-β-induced microglial activation and neuroinflammation [2], [3], [4]. TLR4 is considered a promising therapeutic target for AD [3]. - **Parkinson's disease (PD):** TLR4 polymorphisms have been associated with sporadic PD in a Han Chinese population [5]. - **Major depressive disorder (MDD):** TLR4 SNPs are associated with depressive symptoms and antidepressant efficacy [1]. - **Epilepsy:** Seizure-induced TLR4/MYD88 signaling contributes to microglial activation and neuronal apoptosis [5]. ### 4.6 TLR4 in Metabolic and Cardiovascular Disease - **Type 2 diabetes (T2DM):** TLR4 polymorphisms have been extensively studied for association with T2DM risk, with a meta-analysis suggesting a protective effect of certain variants [6]. TLR4 expression is altered in T1DM patients [7]. - **Diabetic cardiomyopathy:** TLR4 upregulation contributes to cardiac dysfunction in diabetes, and siRNA-mediated silencing of TLR4 reduces diabetic cardiomyopathy in a mouse model [8]. - **Atherosclerosis and insulin resistance:** TLR4 mediates fatty acid-induced insulin resistance [4] and contributes to islet inflammation and beta-cell dysfunction [1]. - **Non-alcoholic fatty liver disease (NAFLD):** TLR4 polymorphisms have been associated with NAFLD susceptibility [2], and CD14 (a TLR4 co-receptor) polymorphisms are also implicated [3]. ### 4.7 TLR4 in Cancer TLR4 has a dual role in cancer, acting as both a tumor promoter and a tumor suppressor depending on the context: - **Tumor-promoting roles:** TLR4 signaling in the tumor microenvironment promotes inflammation, angiogenesis, and immune evasion. TLR4 expression is upregulated in many cancers, including breast cancer [4], hepatocellular carcinoma [5], and colorectal cancer [6]. - **Tumor-suppressing roles:** TLR4 activation can also induce immunogenic cell death and anti-tumor immunity. Paclitaxel, a chemotherapeutic agent, exerts part of its anti-tumor effect by activating TLR4 on tumor-associated macrophages, reprogramming them to an M1 pro-inflammatory phenotype [7], [8]. - **Pan-cancer analysis:** A comprehensive analysis of TLR4 expression across cancers revealed differential expression patterns and associations with prognosis and immune cell infiltration [1]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Interactions TLR4 is the primary sensor of Gram-negative bacterial LPS. However, its role extends beyond LPS detection: - ***Mycobacterium tuberculosis:*** TLR4 recognizes mycobacterial components and contributes to the host defense against tuberculosis. However, *M. tuberculosis* has evolved strategies to subvert TLR4 signaling. Combining TLR4 activation with CLEC4E (Mincle) stimulation induces autophagy, a host-directed strategy to restrict mycobacterial survival [2]. - ***Helicobacter pylori:*** TLR4 recognizes *H. pylori* LPS, and TLR4 polymorphisms influence susceptibility to *H. pylori* infection and peptic ulcer disease [1]. - ***Streptococcus pyogenes* and *Haemophilus influenzae:*** TLR4 polymorphisms modify the risk of tonsillar disease caused by these pathogens [5]. - ***Salmonella enteritidis:*** TLR4 genotype influences resistance to infection in chickens [8]. ### 5.2 Viral Interactions While TLR4 is primarily known for bacterial recognition, it also responds to viral components: - **Respiratory syncytial virus (RSV):** TLR4 recognizes the RSV fusion (F) protein, contributing to the antiviral immune response. - **Hepatitis C virus (HCV):** TLR4 polymorphisms are associated with the risk of HCV-induced hepatocellular carcinoma [4]. - **Grass carp reovirus:** The TLR4 gene cluster in grass carp is involved in the response to this virus [7]. ### 5.3 Fungal and Parasitic Interactions TLR4 also recognizes fungal components, such as those from *Candida albicans*, and contributes to the immune response against parasitic infections. ### 5.4 Immune Evasion Mechanisms Pathogens have evolved multiple strategies to evade or exploit TLR4 signaling: - **LPS modification:** Some bacteria modify their lipid A structure to reduce TLR4 recognition, avoiding immune detection. - **Inhibition of TLR4 signaling:** Certain bacterial effectors can inhibit TLR4 downstream signaling components. - **Exploitation of TLR4 for pathogenesis:** In cerebral cavernous malformations (CCMs), the gut microbiome drives disease progression through TLR4 signaling in endothelial cells, linking the microbiome to a vascular disease [3]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 TLR4 as a Therapeutic Target Given its central role in inflammation and disease, TLR4 is an attractive target for therapeutic intervention. Strategies include small-molecule inhibitors, monoclonal antibodies, siRNA, and natural compounds. ### 6.2 Small-Molecule Inhibitors - **TAK-242 (Resatorvid):** A cyclohexene derivative that binds to the TIR domain of TLR4 and inhibits downstream signaling. TAK-242 has been investigated in clinical trials for sepsis and has shown efficacy in preclinical models of periodontitis [4] and other inflammatory diseases. - **Eritoran (E5564):** A synthetic lipid A analog that acts as a TLR4 antagonist by competitively binding to MD-2. Eritoran was evaluated in a phase III clinical trial for severe sepsis, but did not meet its primary endpoint. - **Rutin:** A natural flavonoid that inhibits the TLR4-MyD88-TRAF6-NF-κB signaling pathway, exerting anti-inflammatory effects [5]. - **Mangiferin and cinnamic acid:** A drug combination that alleviates rheumatoid arthritis by inhibiting TLR4/NF-κB/NLRP3 activation-induced pyroptosis [6]. ### 6.3 Monoclonal Antibodies - **NI-0101:** A humanized monoclonal antibody that binds to TLR4 and blocks LPS-induced signaling. It has been evaluated in clinical trials for rheumatoid arthritis. ### 6.4 Nucleic Acid-Based Therapies - **siRNA:** Small interfering RNAs targeting TLR4 have been shown to attenuate pulmonary inflammation in rat models of acute lung injury [7] and to reduce diabetic cardiomyopathy in mice [8]. Adenovirus-mediated siRNA delivery has been explored for this purpose [7]. - **MicroRNA-based therapies:** miR-146a and miR-223, which negatively regulate TLR4, are being explored as therapeutic agents for diabetic wound healing [2] and acute lung injury [3]. ### 6.5 Natural Compounds and Dietary Interventions - **Paclitaxel:** A chemotherapeutic agent that activates TLR4, reprogramming tumor-associated macrophages to an M1 phenotype and inducing immunogenic cell death [7], [8]. - **Probiotics and prebiotics:** Modulate TLR4 signaling and have been shown to attenuate allergic asthma inflammation [8]. - **In ovo methionine-cysteine injection:** Modulates TLR4 gene expression and antioxidant status in broiler chicks exposed to heat stress [1]. ### 6.6 Pharmacogenomic Considerations TLR4 polymorphisms influence drug responses: - **Paclitaxel:** TLR4 expression levels may predict the efficacy of paclitaxel in ovarian cancer [2]. - **Antidepressants:** TLR4 SNPs are associated with antidepressant efficacy in major depressive disorder [1]. - **Statins:** TLR4 polymorphisms may modify the anti-inflammatory effects of statins. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for TLR4 research. | **Database** | **Identifier** | **URL** | |---|---|---| | **NCBI Gene** | 7099 (human) | https://www.ncbi.nlm.nih.gov/gene/7099 | | **Ensembl** | ENSG00000136869 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136869 | | **UniProt** | O00206 | https://www.uniprot.org/uniprotkb/O00206 | | **RCSB PDB** | 3FXI (TLR4-MD-2-LPS) | https://www.rcsb.org/structure/3FXI | | **OMIM** | 603030 | https://www.omim.org/entry/603030 | | **ClinVar** | Gene: TLR4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TLR4 | | **STRING** | TLR4 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000356824 | | **BioGRID** | TLR4 | https://thebiogrid.org/109341 | | **Gene Ontology (GO)** | GO:0004872 (receptor activity), GO:0007165 (signal transduction), GO:0002376 (immune system process) | https://www.ebi.ac.uk/QuickGO/ | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Poltorak, A., He, X., Smirnova, I., Liu, M., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., & Beutler, B. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science*, 282(5396), 2085–2088. https://www.semanticscholar.org/paper/6fc275b9b84d2ed44352062bbcd4ff9c3203f7d2 [2] Balamurugan, K., Sharan, S., Klarmann, K. D., Zhang, Y., Coppola, V., Summers, G. H., Roger, T., Morrison, D. K., Keller, J. R., & Sterneck, E. (2013). FBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4. *Nature Communications*, 4, 1662. https://www.semanticscholar.org/paper/0edb609e9e5a19e6c016c379f8dae0deecf6df4f [3] Kirino, Y., Zhou, Q., Ishigatsubo, Y., Mizuki, N., Tugal-Tutkun, I., Seyahi, E., Ozyazgan, Y., Ugurlu, S., Erer, B., Abaci, N., Ustek, D., Meguro, A., Ueda, A., Takeno, M., Inoko, H., Ombrello, M. J., Satorius, C. L., Maskeri, B., Mullikin, J. C., Sun, H. W., Gutierrez-Cruz, G., Kim, Y., Wilson, A. F., Kastner, D. L., Gul, A., & Remmers, E. F. (2013). Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. *Proceedings of the National Academy of Sciences of the United States of America*, 110(20), 8134–8139. https://www.semanticscholar.org/paper/955fdad8484053d57e2a779809c975fe0f518af5 [4] Panigrahi, M., Kumar, H., Nayak, S. S., Rajawat, D., Parida, S., Bhushan, B., Sharma, A., & Dutt, T. (2022). Molecular characterization of CRBR2 fragment of TLR4 gene in association with mastitis in Vrindavani cattle. *Microbial Pathogenesis*, 168, 105586. https://www.semanticscholar.org/paper/4b8de35a3d181052b47abfe8aad6ca667b0f01fd [5] Narabayashi, H., Koma, C., Nakata, K., Ikegami, M., Nakanishi, Y., Ogihara, J., Tsuda, M., Hosono, A., Hanazawa, S., & Takahashi, K. (2022). Gut microbiota-dependent adaptor molecule recruits DNA methyltransferase to the TLR4 gene in colonic epithelial cells to suppress inflammatory reactions. *Frontiers in Molecular Biosciences*, 9, 935153. https://www.semanticscholar.org/paper/d539e0a85fe225f77e9443732ba16c52b2c8c7fb [6] Hu, J., Xu, J., Feng, X., Li, Y., Hua, F., & Xu, G. (2021). Differential Expression of the TLR4 Gene in Pan-Cancer and Its Related Mechanism. *Frontiers in Cell and Developmental Biology*, 9, 700661. https://www.semanticscholar.org/paper/50a6fd4dbecb24cac4c69a3dabf25525acf2cfc9 [7] Demirci, M., Bahar Tokman, H., Taner, Z., Keskin, F., Cagatay, P., Ozturk Bakar, Y., Ozyazar, M., Kiraz, N., & Kocazeybek, B. (2020). Bacteroidetes and Firmicutes levels in gut microbiota and effects of hosts TLR2/TLR4 gene expression levels in adult type 1 diabetes patients in Istanbul, Turkey. *Journal of Diabetes and its Complications*, 34(2), 107461. https://www.semanticscholar.org/paper/9c48add60c66f01f9e9278ebd46d5e29bf5c4384 [8] Elwan, H., Elnesr, S. S., Xu, Q., Xie, C., Dong, X., & Zou, X. (2019). Effects of In Ovo Methionine-Cysteine Injection on Embryonic Development, Antioxidant Status, IGF-I and TLR4 Gene Expression, and Jejunum Histomorph